CVS Health (NYSE:CVS) Given New $110.00 Price Target at TD Cowen

CVS Health (NYSE:CVS) had its target price increased by equities research analysts at TD Cowen from $105.00 to $110.00 in a research report issued on Monday,MarketScreener reports. TD Cowen’s price target suggests a potential upside of 20.68% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Piper Sandler dropped their price objective on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Wall Street Zen raised CVS Health from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group boosted their price target on shares of CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday. The Goldman Sachs Group raised their price objective on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Finally, DA Davidson lifted their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.12.

CVS Health Trading Up 0.7%

Shares of CVS stock opened at $91.15 on Monday. CVS Health has a 1-year low of $58.35 and a 1-year high of $90.89. The firm has a market cap of $116.30 billion, a PE ratio of 39.87, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60. The company has a 50-day moving average of $76.86 and a two-hundred day moving average of $78.03. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts predict that CVS Health will post 7.48 EPS for the current year.

Institutional Investors Weigh In On CVS Health

Large investors have recently modified their holdings of the company. Norges Bank acquired a new stake in CVS Health during the 4th quarter worth $1,666,265,000. Wellington Management Group LLP grew its holdings in shares of CVS Health by 193.2% during the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after buying an additional 12,233,675 shares during the last quarter. Amundi increased its position in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after acquiring an additional 3,637,943 shares during the period. Capital Research Global Investors raised its stake in CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock valued at $864,667,000 after acquiring an additional 2,253,531 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in CVS Health by 70.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after acquiring an additional 2,188,307 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.